AP2910A - Novel use of antihistamine agents for the preventative or early treatment of inflammatory syndromes,in particular those triggered by togaviruses - Google Patents

Novel use of antihistamine agents for the preventative or early treatment of inflammatory syndromes,in particular those triggered by togaviruses

Info

Publication number
AP2910A
AP2910A AP2008004613A AP2008004613A AP2910A AP 2910 A AP2910 A AP 2910A AP 2008004613 A AP2008004613 A AP 2008004613A AP 2008004613 A AP2008004613 A AP 2008004613A AP 2910 A AP2910 A AP 2910A
Authority
AP
ARIPO
Prior art keywords
togaviruses
preventative
particular those
early treatment
novel use
Prior art date
Application number
AP2008004613A
Other languages
English (en)
Other versions
AP2008004613A0 (en
Inventor
Jean Derengnaucourt
Etienne Andre
Jacky Tisne-Versailles
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of AP2008004613A0 publication Critical patent/AP2008004613A0/xx
Application granted granted Critical
Publication of AP2910A publication Critical patent/AP2910A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2008004613A 2006-03-09 2007-03-09 Novel use of antihistamine agents for the preventative or early treatment of inflammatory syndromes,in particular those triggered by togaviruses AP2910A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0602087A FR2898271B1 (fr) 2006-03-09 2006-03-09 Nouvelle utilisation d'agents antihistaminiques pour le traitement preventif ou procede de syndromes inflammatoires, en particulier ceux declenches par les toga virus.
PCT/EP2007/052237 WO2007101884A1 (fr) 2006-03-09 2007-03-09 Nouvelle utilisation d'agents antihistaminiques pour le traitement preventif ou precoce de syndromes inflammatoires, en particulier ceux declenches par les togavirus.

Publications (2)

Publication Number Publication Date
AP2008004613A0 AP2008004613A0 (en) 2008-10-31
AP2910A true AP2910A (en) 2014-05-31

Family

ID=37075926

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2008004613A AP2910A (en) 2006-03-09 2007-03-09 Novel use of antihistamine agents for the preventative or early treatment of inflammatory syndromes,in particular those triggered by togaviruses

Country Status (11)

Country Link
US (1) US8242110B2 (xx)
EP (1) EP2007394B1 (xx)
JP (1) JP5550836B2 (xx)
KR (1) KR101450345B1 (xx)
CN (1) CN101394854A (xx)
AP (1) AP2910A (xx)
BR (1) BRPI0709006A2 (xx)
FR (1) FR2898271B1 (xx)
MX (1) MX2008011454A (xx)
WO (1) WO2007101884A1 (xx)
ZA (1) ZA200807442B (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1979311B1 (en) 2005-12-22 2012-06-13 High Point Pharmaceuticals, LLC Phenoxy acetic acids as ppar delta activators
CN102028692B (zh) * 2010-12-01 2012-08-22 中国人民解放军第二军医大学 酮色林的应用
CN103690522B (zh) * 2013-12-08 2015-05-06 武汉威立得生物医药有限公司 一种草酸萘呋胺在制备治疗或预防流感病毒药物中的应用
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CN111886025A (zh) * 2017-11-01 2020-11-03 新加坡国立大学 血清素能药物治疗病毒诱发的血小板减少症的用途
KR20220009954A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
US11071739B1 (en) 2020-09-29 2021-07-27 Genus Lifesciences Inc. Oral liquid compositions including chlorpromazine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3726976A (en) * 1968-03-20 1973-04-10 J Glasser Treatment of arthritis with combinations of antihistaminic compounds and diuretics
JPH0489428A (ja) * 1990-07-30 1992-03-23 Kao Corp 多形核白血球活性化剤
US5492689A (en) * 1991-11-19 1996-02-20 The Center For Innovative Technology Combined virustatic antimediator (COVAM) treatment of common colds
JPH08239327A (ja) * 1995-03-03 1996-09-17 Taisho Pharmaceut Co Ltd 慢性骨格筋疼痛の予防又は治療剤
JP2001151677A (ja) 1999-11-26 2001-06-05 Taisho Pharmaceut Co Ltd 咽頭用組成物
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique

Also Published As

Publication number Publication date
JP5550836B2 (ja) 2014-07-16
EP2007394B1 (fr) 2012-10-10
WO2007101884A1 (fr) 2007-09-13
AP2008004613A0 (en) 2008-10-31
MX2008011454A (es) 2008-09-24
US8242110B2 (en) 2012-08-14
BRPI0709006A2 (pt) 2011-06-21
FR2898271B1 (fr) 2009-01-16
ZA200807442B (en) 2009-07-29
KR101450345B1 (ko) 2014-10-14
KR20080107410A (ko) 2008-12-10
JP2009529514A (ja) 2009-08-20
FR2898271A1 (fr) 2007-09-14
CN101394854A (zh) 2009-03-25
US20090069308A1 (en) 2009-03-12
EP2007394A1 (fr) 2008-12-31

Similar Documents

Publication Publication Date Title
DK2193097T3 (da) Nanostrukturforstærkede kompositartikler og fremgangsmåder
EP1862156A4 (en) VOIDABLE ARTICLES
PL2061385T3 (pl) Urządzenie do zabiegów naczyniowych
HUE054365T2 (hu) Bór-ftalidok terápiás alkalmazásra
ITMI20052085A1 (it) Tutore ambidestro per polso provvisto di immobilizzatore del pollice
DE602006019395D1 (de) Media-behandlungseinrichtung
EP1973525A4 (en) EMULSION-BASED MEDICAL ARTICLES
AP2910A (en) Novel use of antihistamine agents for the preventative or early treatment of inflammatory syndromes,in particular those triggered by togaviruses
LTPA2018503I1 (lt) Kladribino režimas, skirtas išsėtinei sklerozei gydyti
ITMI20050393U1 (it) Impugnatura ribaltabile di sicurezza
FR2881342B1 (fr) Composition demaquillante
IL230165A (en) Medications containing epa, dha or dha derived from epa for the treatment of cell oxidation damage pathology
ITRM20050179A1 (it) Composizione impiegabile per il trattamento delle patologie paradontali.
IL172896A0 (en) Cxcr4 inhibition
DE502006007174D1 (de) Chneidezähnen versehenen werkstücken
GB0525540D0 (en) New treatment
GB0607952D0 (en) Novel treatment
IL182055A0 (en) Agent for prophylaxis or treatment of metabolic syndrome
GB0520611D0 (en) Overflow preventative
EP1878684A4 (en) INDICATOR DEVICE FOR ELEVATOR
AT502107A3 (de) Articles
FR2890858B1 (fr) Composition demaquillante
GB0619344D0 (en) Safe reversing
EP1839653A4 (en) THERAPEUTIC AGENT FOR THE TREATMENT OF SENSORY ANOMALY
GB0523291D0 (en) Treatment table